Q-omics provides the consensus-scored CERCAM profile across patient tissues and cancer cell-line models. CERCAM expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CERCAM is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, CERCAM RNA expression shows 20,566 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where CERCAM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CERCAM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CERCAM survival associations across molecular data types. CERCAM RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CERCAM RNA expression–survival associations across cancer types. High CERCAM expression shows unfavorable associations in KIRP, KIRC, MESO, BLCA, ACC and CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CERCAM RNA expression.
This table summarizes CERCAM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CERCAM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CERCAM shows lower tumor expression in KICH and higher tumor expression in HNSC, LUSC, LUAD, COAD and BRCA. The HNSC box plot shows higher CERCAM RNA expression in tumor versus normal tissue (log2 FC = +3.210, t-test p < 0.001).
This table shows molecular features associated with CERCAM in patient tissues and cancer cell lines. In patient samples, CERCAM shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CERCAM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
